Circulating levels of galectin-9 are a potential biomarker of survival in advanced non-small-cell lung cancer.

Guilherme Vieira de Mendonça FilhoGuilherme Jorge CostaMário Rino MartinsLeuridan C Torres

Published in: Journal of surgical oncology (2024)

This study indicated an association of tobacco with the release of circulating sGal-9 levels and the accuracy of sGal-9 as a potential biomarker predictive of survival time in advanced NSCLC patients. Furthermore, sGal-9 has may be a potential therapeutic target in the advanced NSCLC.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
end stage renal disease
chronic kidney disease
newly diagnosed
peritoneal dialysis
free survival
prognostic factors
patient reported outcomes
brain metastases
climate change